Literature DB >> 8119685

Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis.

D G Doherty1, P T Donaldson, J A Underhill, J M Farrant, A Duthie, G Mieli-Vergani, I G McFarlane, P J Johnson, A L Eddleston, A P Mowat.   

Abstract

Susceptibility to autoimmune hepatitis in white patients is associated with the human leukocyte antigen class II antigens DR3 and DR4. To analyze the molecular basis of these associations, we used oligonucleotide probes to determine the DRB, DQA and DQB hypervariable nucleotide sequences in 119 patients with autoimmune hepatitis and 177 matched controls. DRB3*0101, which encodes DR52a, predisposed patients most strongly to the disease. It was present in 58% of patients and 25% of controls (corrected P < 0.000005), whereas DQA1*0101 and 0102 conferred protection in males only. The DR4 subtype, DRB1*0401, was raised in the DRB3*0101-negative patients; 81% possessed either DRB3*0101 or DRB1*0401, compared with 42% of controls (corrected P < 0.0000001). These alleles encode the amino acid sequence Leu-Leu-Glu-Gln-Lys-Arg at positions 67 to 72 of the DR beta polypeptide, which was present in 94% of patients and 64% of controls (corrected P < 0.000001) and in all patients who tested positive for autoantibodies to the hepatic asialoglycoprotein receptor. The patients with DRB1*0401 had less severe disease, relapsed less frequently and were first seen significantly later in life than those patients with DRB3*0101; and whereas a single copy of DRB1*0401 predisposed to autoimmune hepatitis, DRB3*0101-associated susceptibility had a dose-related effect. These data provide evidence that specific residues in the DR beta polypeptides predispose to autoimmune hepatitis in white patients and genes linked to DRB3*0101 and DRB1*0401 may determine two clinically distinct disease patterns.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8119685     DOI: 10.1002/hep.1840190311

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  49 in total

Review 1.  Genetic bases of autoimmune hepatitis.

Authors:  Albert J Czaja; Derek G Doherty; Peter T Donaldson
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

Review 2.  New insights into the functional role of the rheumatoid arthritis shared epitope.

Authors:  Denise E de Almeida; Song Ling; Joseph Holoshitz
Journal:  FEBS Lett       Date:  2011-03-22       Impact factor: 4.124

Review 3.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

4.  The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis.

Authors:  I G McFarlane
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

5.  MHC molecules in health and disease: At the cusp of a paradigm shift.

Authors:  Denise E de Almeida; Joseph Holoshitz
Journal:  Self Nonself       Date:  2011-01-01

Review 6.  Autoimmune hepatitis.

Authors:  G Mieli-Vergani; D Vergani
Journal:  Arch Dis Child       Date:  1996-01       Impact factor: 3.791

Review 7.  Pathogens and autoimmune hepatitis.

Authors:  U Christen; E Hintermann
Journal:  Clin Exp Immunol       Date:  2018-10-07       Impact factor: 4.330

8.  Acute exacerbation of autoimmune hepatitis induced by Twinrix.

Authors:  Antal Csepregi; Gerhard Treiber; Christoph Röcken; Peter Malfertheiner
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

Review 9.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

10.  The induction of autoimmune hepatitis in the human leucocyte antigen-DR4 non-obese diabetic mice autoimmune hepatitis mouse model.

Authors:  M Yuksel; X Xiao; N Tai; Manakkat Vijay; E Gülden; K Beland; P Lapierre; F Alvarez; Z Hu; I Colle; Y Ma; L Wen
Journal:  Clin Exp Immunol       Date:  2016-08-23       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.